Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A compound of the following chemical structure (I), or a pharmaceutically acceptable salt thereof:



(I)

Claim 2. (currently amended) A compound having the following physicochemical properties, or a pharmaceutically acceptable salt thereof:

1) Property : Basic liposoluble powder

2) Molecular formula : $C_{55}H_{98}N_8O_{14}$

3) Molecular weight : 1094 (FAB-MS method)

4) High resolution FAB-MS $[M+H]^+$

calculated for $C_{55}H_{99}N_8O_{14}$ 1095.7281

found 1095.7365

5) Ultra violet absorption spectrum : End absorption

6) Infra red absorption spectrum (KBr pellet, cm^{-1})

3434, 3335, 2962, 2937, 2875, 2806, 1750, 1684, 1641, 1509, 1469, 1412, 1371, 1314, 1294, 1271, 1204, 1156, 1128, 1074, 1020

7) Optical rotation : $[\alpha]_D^{25}$ -120° (c 1.0, methanol)

8) ^1H NMR spectrum (in $CDCl_3$, 500 MHz, δ(ppm), internal standard: tetramethylsilane):

0.78(3H), 0.79(3H), 0.80(3H), 0.82(3H), 0.87(3H), 0.88(1H), 0.92(3H), 0.93(3H), 0.94(3H), 0.96(3H), 0.97(3H), 0.98(3H), 1.01(3H), 1.02(3H), 1.03(3H), 1.06(3H), 1.21(1H), 1.41(3H), 1.41(1H), 1.48(1H), 1.48(1H), 1.49(1H), 1.52(3H), 1.55(1H), 1.65(1H), 1.66(1H), 1.70(2H), 1.73(1H), 1.81(1H), 1.87(1H), 2.28(1H), 2.31(1H), 2.37(1H), 2.48(3H), 2.89(3H), 2.94(3H), 2.96(1H), 3.29(3H), 3.56(1H), 4.06(1H), 4.14(1H), 4.77(1H),

4.78(1H), 4.84(1H), 4.91(1H), 4.96(1H), 5.21(1H), 5.25(1H), 5.53(1H), 6.39(1H), 7.83(1H), 7.94(1H), 8.28(1H)

9) ^{13}C NMR spectrum (in $CDCl_3$, 500 MHz, δ (ppm), internal standard : tetramethylsilane):

10.9(q), 11.9(q), 15.0(q), 15.1(q), 16.0(q), 16.6(q), 17.4(q), 18.3(q), 18.6(q), 18.7(q), 19.1(q), 21.0(q), 21.4(q), 22.1(q), 23.1(q), 23.51(q), 23.54(q), 24.2(t), 24.6(d), 24.8(d), 25.4(d), 25.5(t), 27.7(d), 29.5(q), 29.8(d), 30.2(q), 36.1(q), 36.5(t), 37.7(t), 38.3(d), 38.4(d), 39.7(t), 40.9(q), 46.2(d), 51.8(d), 53.1(d), 54.7(d), 55.1(d), 63.9(d), 64.7(d), 68.1(d), 70.1(d), 73.4(d), 74.3(d), 77.1(d), 169.03(s), 169.04(s), 169.6(s), 169.8(s), 169.9(s), 170.3(s), 172.0(s), 173.4(s), 173.8(s), 174.0(s)

~~10) High performance liquid chromatography~~**[[:]]**

~~Column~~ **[[:]]** ~~Shodex Asahipak C8P-50 4E (diameter 4.6 mm x length 250 mm (product of Showa Denko K.K.)~~

~~Mobile phase~~ **[[:]]** ~~Acetonitrile~~ **[[:]]** ~~10 mM aqueous ammonium hydrogencarbonate solution~~ **[[**= 13:7**]]**

~~Flow rate~~ **[[:]]** ~~0.7 ml/minute~~

~~Wave length of detection~~**[[:]]** ~~λ 210 nm~~

~~Retention time~~ **[[:]]** ~~10.20 minutes~~

~~11)~~ 10) Solubility : soluble in dimethylsulfoxide, methanol, and chloroform

~~12)~~ 11) Amino acid analysis : Threonine, alanine and isoleucine were detected from the hydrolysate.

Claim 3. (currently amended) A compound of the following chemical structure (II):



(II)

Claim 4. (currently amended) A compound having the following physicochemical properties:

1) Property : Neutral liposoluble powder

2) Molecular formula: $C_{57}H_{100}N_8O_{15}$

3) Molecular weight : 1136 (FAB-MS method)

4) High resolution FAB-MS $[M+H]^+$

calculated for $C_{57}H_{101}N_8O_{15}$ 1137.7387

found 1137.7410

5) Ultra violet absorption spectrum : End absorption

6) Infra red absorption spectrum (KBr pellet, cm^{-1})

3433, 3333, 2963, 2937, 2875, 1751, 1686, 1642, 1516, 1469, 1409, 1388, 1372, 1311, 1292, 1272, 1201, 1156, 1128, 1074, 1017

7) Optical rotation : $[\alpha]_D^{25}$ -131°(c 1.0, methanol)

8) ^1H NMR spectrum (in $CDCl_3$, 500 MHz, δ (ppm), internal standard : tetramethylsilane):

0.78(3H), 0.79(3H), 0.80(3H), 0.83(3H), 0.87(1H), 0.87(3H), 0.90(3H), 0.92(3H), 0.93(3H), 0.95(3H), 0.95(3H), 0.98(3H), 0.98(3H), 1.01(3H), 1.01(3H), 1.03(1H), 1.05(3H), 1.28(3H), 1.37(1H), 1.40(1H), 1.46(1H), 1.47(1H), 1.49(1H), 1.51(3H), 1.64(1H), 1.65(1H), 1.66(1H), 1.86(1H), 1.72(1H), 1.78(1H), 2.12(3H), 2.13(1H), 2.26(1H), 2.31(1H), 2.37(1H), 2.88(3H), 2.93(3H), 2.97(3H), 3.28(3H), 3.56(1H), 4.03(1H), 4.15(1H), 4.73(1H), 4.78(1H), 4.82(1H), 4.83(1H), 4.91(1H), 4.97(1H), 5.15(1H), 5.28(1H), 5.50(1H), 6.37(1H), 6.87(1H), 7.86(1H), 8.29(1H)[[.]]

9) ^{13}C NMR spectrum (in $CDCl_3$, 500 MHz, δ (ppm), internal standard : tetramethylsilane):

10.5(q), 10.9(q), 14.9(q), 15.1(q), 15.6(q), 16.6(q), 16.7(q), 18.3(q), 18.6(q), 18.7(q), 19.0(q), 20.8(q), 21.4(q), 22.0(q), 22.1(q), 23.1(q), 23.6(q), 23.6(q), 24.1(t), 24.6(t), 24.7(d), 24.8(d), 25.4(d), 27.7(d), 29.5(q), 29.8(d), 30.2(q), 31.6(d), 31.8(q), 36.1(t), 37.6(t), 38.4(d), 39.6(t), 40.9(q), 46.1(d), 51.8(d), 53.1(d), 54.7(d), 54.7(d), 61.2(d), 63.9(d), 64.6(d), 68.1(d), 73.1(d), 74.3(d), 77.0(d), 168.9(s), 168.9(s), 169.1(s), 169.9(s), 169.9(s), 170.3(s), 170.6(s), 171.7(s), 172.0(s), 173.3(s), 173.8(s)

~~10) High performance liquid chromatography~~

~~Column~~ **[[:]]** ~~Shodex Asahipak C8P 50 4E (diameter 4.6 mm x length 250 mm (product of Showa Denko K.K.)~~

~~Mobile phase~~ **[[:]]** ~~Acetonitrile~~ **[[:]]** ~~10 mM aqueous ammonium hydrogencarbonate solution~~ **[[**=13:7**]]**

~~Flow rate~~**[[:]]** ~~0.7 ml/minute~~

~~Wave length of detection~~ **[[:]]** ~~λ 210 nm~~

~~Retention time~~ **[[:]]** ~~9.05 minutes~~

~~11)~~ 10) Solubility : Soluble in dimethylsulfoxide, methanol, and chloroform

12) 11) Amino acid analysis : Threonine, alanine and isoleucine were detected from the hydrolysate.

Claim 5. (currently amended) A process for preparing **[[**a**]]** the compound according to claim 1, comprising fermenting a microorganism ~~that belongs to the~~ which is Phoma ~~genus~~ sp. SANK 13899 (FERM BP-6851) strain, and produces **[[**a**]]** the compound according to claim 1, and isolating **[[**a**]]** the compound according to claim 1 from the fermentation product of said microorganism.

Claim 6. (currently amended) A process for preparing **[[**a**]]** the compound according to claim 2, comprising fermenting a microorganism ~~that belongs to the~~ which is Phoma ~~genus~~ sp. SANK 13899 (FERM BP-6851) strain, and produces **[[**a**]]** the compound according to claim 2, and isolating **[[**a**]]** the compound according to claim 2 from the fermentation product of said microorganism.

Claim 7. (currently amended) A process for preparing **[[**a**]]** the compound according to claim 3, comprising fermenting a microorganism ~~that belongs to the~~ which is Phoma ~~genus~~ sp. SANK 13899 (FERM BP-6851) strain, and produces **[[**a**]]** the compound according to claim 3, and isolating **[[**a**]]** the compound according to claim 3 from the fermentation product of said

Claim 8. (currently amended) A process for preparing **[[a]]** the compound according to claim 4, comprising fermenting a microorganism ~~that belongs to the~~ which is Phoma ~~genus~~ sp. SANK 13899 (FERM BP-6851) strain, and produces **[[a]]** the compound according to claim 4, and isolating **[[a]]** the compound according to claim 4 from the fermentation product of said microorganism.

Claims 9 to 12 (canceled).

Claim 13. (withdrawn) Phoma sp. SANK 13899 (FERM BP-6851) strain.

Claim 14. (currently amended) A fungicidal composition comprising a fungicidally effective amount of **[[a]]** the compound according to claim 1 as an active ingredient in combination with a pharmaceutically acceptable carrier.

Claim 15. (currently amended) A fungicidal composition comprising a fungicidally effective amount of **[[a]]** the compound according to claim 2 as an active ingredient in combination with a pharmaceutically acceptable carrier.

Claim 16. (currently amended) A fungicidal composition comprising a fungicidally effective amount of **[[a]]** the compound according to claim 3 as an active ingredient in combination with a pharmaceutically acceptable carrier.

Claim 17. (currently amended) A fungicidal composition comprising a fungicidally effective amount of **[[a]]** the compound according to claim 4 as an active ingredient in combination with a pharmaceutically acceptable carrier.

Claim 18. (currently amended) A method for treating ~~or preventing~~ an infectious fungal disease, which comprises administering a pharmaceutically effective amount of **[[a]]** the compound according to claim 1 to a human or a non-human animal, wherein the infectious fungal disease is at least one disease selected from the group consisting of (i) a deepseated mycosis and a systemic mycosis, which is selected from the group consisting of *aspergillosis*, *cryptococcosis* and *candidiasis*, and (ii) a superficial mycosis of *candidiasis*.

Claim 19. (original) The method of claim 18, wherein the compound is administered to a human.

Claim 20. (canceled)

Claim 21. (currently amended) A method for treating ~~or preventing~~ an infectious fungal disease, which comprises administering a pharmaceutically effective amount of **[[**a**]]** the compound according to claim 2 to a human or a non-human animal, wherein the infectious fungal disease is at least one disease selected from the group consisting of (i) a deepseated mycosis and a systemic mycosis, which is selected from the group consisting of *aspergillosis*, *cryptococcosis* and *candidiasis*, and (ii) a superficial mycosis of *candidiasis*.

Claim 22. (original) The method of claim 21. wherein the compound is administered to a human.

Claim 23. (canceled)

Claim 24. (currently amended) A method for treating ~~or preventing~~ an infectious fungal disease, which comprises administering a pharmaceutically effective amount of **[[**a**]]** the compound according to claim 3 to a human or a non-human animal, wherein the infectious fungal disease is at least one disease

selected from the group consisting of a deepseated mycosis and a systemic mycosis, which is *cryptococcosis*.

Claim 25. (original) The method of claim 24, wherein the compound is administered to a human.

Claim 26. (canceled)

Claim 27. (currently amended) A method for treating ~~or preventing~~ an infectious fungal disease, which comprises administering a pharmaceutically effective amount of **[[a]]** the compound according to clam 4 to a human or a non-human animal, wherein the infectious fungal disease is at least one disease selected from the group consisting of a deepseated mycosis and a systemic mycosis, which is *cryptococcosis*.

Claim 28. (original) The method of claim 27, wherein the compound is administered to a human.

Claim 29. (canceled)

Claim 30. (currently amended) A compound having the following physicochemical properties or a salt thereof:

1) property : basic and liposoluble powder

2) ultra violet absorption spectrum : end absorption

3) ^{1}H-NMR (in $CDCl_3$, 500 MHz, δ ppm, internal standard : tetrametaylsilane):

0.78(3H), 0.79(3H), 0.80(3H), 0.82(3H), 0.87(3H), 0.88(1H), 0.92(3H), 0.93(3H), 0.94(3H), 0.96(3H), 0.97(3H), 0.98(3H), 1.01(3H), 1.02(3H), 1.03(3H), 1.06(3H), 1.21(1H), 1.41(3H), 1.41(1H), 1.48(1H), 1.48(1H), 1.49(1H), 1.52(3H), 1.55(1H), 1.65(1H), 1.66(1H), 1.70(2H), 1.73(1H), 1.81(1H), 1.87(1H), 2.29(1H), 2.31(1H), 2.37(1H), 2.48(3H), 2.89(3H), 2.94(3H), 2.96(1H), 3.29(3H), 3.56(1H), 4.06(1H), 4.14(1H), 4.77(1H), 4.78(1H), 4.84(1H), 4.91(1H), 4.96(1H), 5.21(1H), 5.25(1H), 5.53(1H), 6.39(1H), 7.83(1H), 7.94(1H), 8.28(1H)

4) ^{13}C NMR spectrum (in $CDCl_3$, 500 MHz, δ ppm, internal standard : tetramethylsilane) :

10.9(q), 11.9(q), 15.0(q), 15.1(q), 16.0(q), 16.6(q), 17.4(q), 18.3(q), 18.6(q), 18.7(q), 19.1(q), 21.0(q), 21.4(q), 22.1(q), 23.1(q), 23.51(q), 23.54(q), 24.2(t), 24.6(d), 24.8(d), 25.4(d), 25.5(t), 27.7(d), 29.5(q), 29.8(d), 30.2(q), 36.1(q), 36.5(t), 37.7(t), 38.3(d), 38.4(d), 39.7(t), 40.9(q), 46.2(d), 51.8(d),

53.1(d), 54.7(d), 55.1(d), 63.9(d), 64.7(d), 68.1(d), 70.1(d), 73.4(d), 74.3(d), 77.1(d), 169.03(s), 169.04(s), 169.6(s), 169.8(s), 169.9(s), 170.3(s), 172.0(s), 173.4(s), 173.8(s), 174.0(s)

~~5) high performance liquid chromatography~~ **[[:]]**

~~column~~ **[[:]]** ~~Shodex Asahipak C8P-50 4E (diameter 4.6 mm x length 250 mm (product of Showa Denko K.K.)~~

~~mobile phase~~ **[[:]]** ~~acetonitrile~~ **[[:]]** ~~10 mM aqueous ammonium hydrogencarbonate solution~~ **[[**=13:7**]]**

~~flow rate~~ **[[:]]** ~~0.7 ml/minute~~

~~detection wave length of~~ **[[:]]** ~~λ 210 nm~~

~~retention time~~ **[[:]]** ~~10.20 minute~~

~~6)~~ 5) solubility : soluble in dimethylsulfoxide, methanol, and chloroform

~~7)~~ 6) amino acid analysis : hydrolysis products are threonine, alanine and isoleucine.

Claim 31. (currently amended) A process for preparing the compound of claim 30 which comprises isolation of the compound from **[[**the**]]** an incubation product of a microorganism that ~~belongs to the~~ is Phoma ~~genus~~ sp. SANK 13899 (FERM BP-6851) strain and which produces the compound.

Claim 32. (canceled)

Claim 33. (new) The method of claim 18, wherein the fungal disease is selected from the group consisting of a deepseated mycosis and a systemic mycosis, which is selected from the group consisting of *aspergillosis, cryptococcosis* and *candidiasis*.

Claim 34. (new) The method of claim 21, wherein the fungal disease is selected from the group consisting of a deepseated mycosis and a systemic mycosis, which is selected from the group consisting of *aspergillosis, cryptococcosis* and *candidiasis*.

Claim 35. (new) The method of claim 18 wherein the fungal disease is caused by *Candida albicans*.

Claim 36. (new) The method of claim 18, wherein the fungal disease is caused by *Aspergillus fumigatus*.

Claim 37. (new) The method of claim 18, wherein the fungal disease is caused by *Cryptococcus neoformans*.

Claim 38. (new) The method of claim 21, wherein the fungal disease is caused by *Candida alibcans*.

Claim 39. (new) The method of claim 21, wherein the fungal disease is caused by *Aspergillus fumigatus*.

Claim 40. (new) The method of claim 21, wherein the fungal disease is caused by *Cryptococcus neoformans*.

Claim 41. (new) The method of claim 24, wherein the fungal disease is caused by *Cryptococcus neoformans*.

Claim 42. (new) The method of claim 27, wherein the fungal disease is caused by *Cryptococcus neoformans*.